Trials / Completed
CompletedNCT02518061
11C-Methionine PET as Prognostic Marker of Gliomas
Role of 11C-Methionine PET for the Prognostic and Molecular Characterization of Gliomas Candidate to Surgery.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 145 (actual)
- Sponsor
- Istituto Clinico Humanitas · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a retrospective study that involves the revision of clinical, instrumental and pathologic data of an estimated cohort of maximum 145 patients with glioma treated with surgery with radical intent at our center.
Detailed description
This is a retrospective observation that involves the revision of clinical, instrumental and pathologic data of an estimated cohort of 145 patients with glioma treated with surgery with radical intent at our center. We will review 11C-Methionine PET data acquired within 30 days prior to surgery and analyze its principal imaging characteristics with respect to IDH1 mutation status, MGMT promoter methylation and 1p/19q co-deletion. These markers will be studied on tumor tissue obtained at surgery, used for diagnostic purposes and stored in paraffin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | This is a retrospective study |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2018-12-31
- Completion
- 2018-12-31
- First posted
- 2015-08-07
- Last updated
- 2020-10-01
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT02518061. Inclusion in this directory is not an endorsement.